Orphan Drug Designations, Invitations to Investors Conferences, and Stock Price updates - Research Report on Teva, Cubist,

  Orphan Drug Designations, Invitations to Investors Conferences, and Stock
  Price updates - Research Report on Teva, Cubist, Community Health Systems,
                          Aegerion, and Air Methods

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 6, 2013

NEW YORK, December 6, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Teva
Pharmaceutical Industries (NYSE: TEVA), Cubist Pharmaceuticals Inc. (NASDAQ:
CBST), Community Health Systems, Inc. (NYSE: CHS), Aegerion Pharmaceuticals,
Inc. (NASDAQ: AEGR), and Air Methods Corp. (NASDAQ: AIRM). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

Teva Pharmaceutical Industries Research Report

On November 27, 2013, Teva Pharmaceutical Industries (Teva) announced that the
U.S. Food and Drug Administration (FDA) has granted orphan drug exclusivity
for TREANDA all through October 2015 for indolent B-cell non-Hodgkin lymphoma
(iNHL) that has advanced during or within six months of treatment with
rituximab or a rituximab-containing regimen. Bill Campbell, Vice President and
General Manager, Teva Oncology, commented, "Since 2008, TREANDA has played a
significant role in the treatment of patients with iNHL that has progressed.
We are pleased the FDA has recognized our commitment to treating patients with
this rare form of cancer." Further, the Company stated that TREANDA is also
indicated for the treatment of patients with chronic lymphocytic leukemia
(CLL). TREANDA has been granted orphan drug exclusivity for this indication
through March 2015. Teva also stated that with the previously granted six
months of pediatric exclusivity for TREANDA, regulatory exclusivity for this
indication will last until September 20, 2015. The Full Research Report on
Teva Pharmaceutical Industries - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/e3a3_TEVA

--

Cubist Pharmaceuticals Inc. Research Report

On December 3, 2013, Cubist Pharmaceuticals Inc.'s (Cubist) stock declined
2.54%, ending the day at $65.99. Over the previous three trading sessions,
shares of Cubist declined 3.21% compared to the Nasdaq Composite which also
declined 0.19% during the same period. The Full Research Report on Cubist
Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/92f2_CBST

--

Community Health Systems, Inc. Research Report

On December 3, 2013, Community Health Systems, Inc. (CHS) announced that its
management will participate in the Oppenheimer 24th Annual Healthcare
Conference, to be held on December 10-11, 2013, at the Crowne Plaza Times
Square in New York City. CHS informed that the Company presentation is
scheduled to begin at 8:35 a.m. ET (7:35 a.m. CT), on Tuesday, December 10,
2013. Further, a link to the broadcast will be available at the investor
relations section of the Company's website, where a replay will also be
available for 30 days. The Full Research Report on Community Health Systems,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/7587_CYH

--

Aegerion Pharmaceuticals, Inc. Research Report

On December 3, 2013, Aegerion Pharmaceuticals, Inc.'s (Aegerion) stock
declined 2.41%, ending the day at $68.37. Over the previous three trading
sessions, shares of Aegerion dropped 4.40% compared to the Nasdaq Composite
which also declined 0.19% during the same period. The Full Research Report on
Aegerion Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/a3f6_AEGR

--

Air Methods Corp. Research Report

On December 3, 2013, Air Methods Corp.'s (Air Methods) stock increased 0.18%,
ending the day at $55.49. Over the previous three trading sessions, shares of
Air Methods declined 0.38% compared to the Nasdaq Composite which also
declined 0.19% during the same period. The Full Research Report on Air Methods
Corp. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/ff38_AIRM

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas; +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.